The gene therapy strategy of mutation compensation is designed to rectify the molecular lesions that are etiologic for neoplastic transformation. For dominant oncogenes, such approaches involve the functional knockout of the dysregulated cellular control pathways provoked by the overexpressed oncoprotein. On this basis, molecular interventions may be targeted to the transcriptional level of expression, via antisense or ribozymes, or post-transcriptionally, via intracellular single chain antibodies (intrabodies). For carcinoma of the breast, these approaches have been applied in the context of the disease linked oncogenes erbB-2 and cyclin D1, as well as the estrogen receptor. Neoplastic revision accomplished in modal systems has rationalized human trials on this basis.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalBreast Cancer Research
Issue number1
StatePublished - 2000


  • Antisense
  • Dominant-negative
  • Gene therapy
  • Oncogene
  • Ribozyme


Dive into the research topics of 'Gene therapy for carcinoma of the breast genetic ablation strategies'. Together they form a unique fingerprint.

Cite this